Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Olema Pharmaceuticals, Inc. - Common Stock
(NQ:
OLMA
)
8.040
+0.770 (+10.59%)
Delayed Quote
Updated: 4:00 PM EST, Nov 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Olema Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
November 10, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium
November 04, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
November 02, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
August 31, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
August 13, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
August 10, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
May 26, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
May 21, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
May 19, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
May 12, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
April 29, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
April 21, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
April 17, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
March 17, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
March 16, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA
March 09, 2026
From
DJS Law Group
Via
Business Wire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
February 19, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
February 04, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces Departure of Chief Operating and Financial Officer
January 30, 2026
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2026
From
Olema Oncology
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
